Literature DB >> 9131757

A partially grouped logrank test.

R Sposto1, D Stablein, S Carter-Campbell.   

Abstract

We propose a modified version of the standard logrank test for survival data in which the first contribution to the statistic is based on grouping of data before a pre-selected grouping time. The grouping is accomplished by artificially constructing the first table based on the product limit estimates of the proportions surviving at the grouping time. Remaining contributions to the statistic are identical to that of the standard logrank statistic. The approach has the advantage of being uninfluenced by non-proportional hazards differences prior to the grouping time while being almost as efficient as the usual logrank test for proportional-hazards alternatives. The statistic is particularly useful for interim monitoring in situations where early difference between treatments are unimportant and/or lagged treatment effects are anticipated. We report simulation studies to verify and investigate the test's properties.

Mesh:

Year:  1997        PMID: 9131757     DOI: 10.1002/(sici)1097-0258(19970330)16:6<695::aid-sim436>3.0.co;2-c

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

Review 1.  Immunotherapy in prostate cancer: emerging strategies against a formidable foe.

Authors:  Marijo Bilusic; Christopher Heery; Ravi A Madan
Journal:  Vaccine       Date:  2011-07-07       Impact factor: 3.641

Review 2.  Group sequential tests for long-term survival comparisons.

Authors:  Brent R Logan; Shuyuan Mo
Journal:  Lifetime Data Anal       Date:  2014-07-23       Impact factor: 1.588

3.  Comparing treatments in the presence of crossing survival curves: an application to bone marrow transplantation.

Authors:  Brent R Logan; John P Klein; Mei-Jie Zhang
Journal:  Biometrics       Date:  2008-01-11       Impact factor: 1.701

Review 4.  Improved endpoints for cancer immunotherapy trials.

Authors:  Axel Hoos; Alexander M M Eggermont; Sylvia Janetzki; F Stephen Hodi; Ramy Ibrahim; Aparna Anderson; Rachel Humphrey; Brent Blumenstein; Lloyd Old; Jedd Wolchok
Journal:  J Natl Cancer Inst       Date:  2010-09-08       Impact factor: 13.506

5.  Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial.

Authors:  Jurjen J Boonstra; Tjebbe C Kok; Bas Pl Wijnhoven; Mark van Heijl; Mark I van Berge Henegouwen; Fiebo Jw Ten Kate; Peter D Siersema; Winand Nm Dinjens; Jan Jb van Lanschot; Hugo W Tilanus; Ate van der Gaast
Journal:  BMC Cancer       Date:  2011-05-19       Impact factor: 4.430

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.